LL-37

What LL-37 Does

LL-37 (leucine-leucine-37) is the only human cathelicidin antimicrobial peptide. It is a 37-amino-acid peptide cleaved from the precursor protein hCAP-18 by proteinase 3. Your body produces LL-37 as a front-line innate immune defense — it is released by neutrophils, macrophages, and epithelial cells when they encounter pathogens.

The mechanisms that matter for your protocol:

• Direct antimicrobial killing — LL-37 inserts into bacterial cell membranes and forms pores, causing membrane disruption and cell death. This mechanism is effective against gram-positive bacteria, gram-negative bacteria, fungi, and some enveloped viruses
• Biofilm disruption — LL-37 degrades the extracellular polymeric substance (EPS) matrix that protects biofilm communities, exposing bacteria to immune cells and antibiotics. This is the single most valuable property of LL-37 for chronic infections
• Immune cell recruitment — LL-37 acts as a chemoattractant for neutrophils, monocytes, and T-cells, directing immune cells to infection sites
• Wound healing — promotes epithelial cell migration and proliferation, supporting wound closure
• Endotoxin neutralization — binds and neutralizes lipopolysaccharide (LPS), the bacterial toxin that drives sepsis and systemic inflammatory response

The Biofilm Problem

Biofilms are the reason many chronic infections resist treatment:

Feature	Planktonic Bacteria	Biofilm Bacteria
Organization	Free-floating, individual	Structured community in protective matrix
Antibiotic resistance	Standard susceptibility	Up to 1,000x more resistant
Immune evasion	Normal immune targeting	Matrix shields from immune cells
Recurrence	Cleared by antibiotics	Regrows from protected cells when antibiotics stop
Detection	Standard cultures	Often missed on standard cultures

Conditions associated with biofilms:

• Chronic sinusitis
• Recurrent UTIs
• Chronic Lyme disease co-infections
• Chronic wound infections
• Device-associated infections (implants, catheters)
• Chronic otitis media
• Dental infections (periodontal disease)

LL-37 addresses the core problem — it attacks the biofilm architecture itself, not just the bacteria inside.

Dosing Protocol

Standard Antimicrobial Protocol

Parameter	Detail
Starting dose	50 mcg/day
Full dose	100 mcg/day
Cycle length	4–6 weeks
Off period	4 weeks minimum
Injection site	Subcutaneous (rotate sites — LL-37 causes more site irritation than most peptides)

Titration

Week	Dose	Frequency
1	50 mcg	Once daily
2–6	100 mcg	Once daily

Starting at 50 mcg for the first week reduces injection-site reactions as your body adjusts.

Timing

No specific timing requirements. LL-37 does not interact with food, insulin, or circadian rhythms. Many users inject in the morning for convenience.

Advanced: Combining with Antibiotics

For biofilm-associated chronic infections, some practitioners use LL-37 as an adjunct to antibiotic therapy:

1. Start LL-37 — 1 week of LL-37 alone to begin biofilm disruption
2. Add antibiotics — begin antibiotic course while continuing LL-37
3. Continue LL-37 for full cycle — maintain LL-37 through and 1–2 weeks beyond the antibiotic course

The rationale: LL-37 disrupts biofilms first, exposing bacteria to the antibiotics that follow. This requires physician supervision — coordinate with your prescriber.

LL-37 Antimicrobial Spectrum

Published Activity Against

Organism Category	Examples	Mechanism
Gram-positive bacteria	S. aureus (including MRSA), S. epidermidis, E. faecalis	Membrane disruption
Gram-negative bacteria	E. coli, P. aeruginosa, K. pneumoniae	Membrane disruption + LPS neutralization
Fungi	Candida albicans, Candida krusei	Membrane disruption
Enveloped viruses	Influenza, HSV, RSV	Viral envelope disruption
Mycobacteria	M. tuberculosis (in vitro)	Membrane disruption

Resistance Considerations

Bacterial resistance to LL-37 is rare compared to conventional antibiotics because:

1. LL-37 attacks a fundamental structural component (the cell membrane), not a metabolic pathway
2. The mechanism of action is physical disruption, not enzyme inhibition
3. Developing resistance to membrane-targeting peptides requires extensive membrane remodeling — energetically expensive for bacteria

However, some bacteria have evolved partial resistance mechanisms (protease degradation of LL-37, surface charge modification). Complete resistance is rare.

Safety & Contraindications

Side Effects

Side Effect	Frequency	Notes
Injection-site reaction	Very common	LL-37 is inherently membrane-active; expect more irritation than other peptides. Rotate sites aggressively.
Injection-site pain	Common	Stinging during injection. Warming the solution helps.
Redness/induration	Common	May persist 12–24 hours. Not an infection sign unless spreading.
Mild flu-like symptoms	Occasional	Possible immune activation effect, usually first 2–3 days

Managing Injection-Site Reactions

LL-37 causes more site irritation than most peptides because it is literally designed to interact with cell membranes. Strategies:

1. Rotate sites aggressively — never use the same spot within 7 days
2. Warm the solution — roll vial between palms for 30 seconds before drawing
3. Start at 50 mcg — the lower starting dose gives tissue time to adjust
4. Inject slowly — 10+ seconds for the full injection
5. Ice the site after — 5 minutes of ice reduces inflammation

Contraindications

• Active autoimmune disease — LL-37 activates immune responses; could exacerbate autoimmune flares
• Concurrent immunosuppressant therapy — potential pharmacological conflict
• Pregnancy/breastfeeding — no safety data
• Under 18 — no pediatric data
• Allergy to cathelicidin proteins — rare but possible

Blood Work

Marker	When	Why
CBC with differential	Baseline + 4 weeks	Monitor immune cell response
CRP	Baseline + 4 weeks	Track inflammatory status
CMP	Baseline	Liver and kidney function

For chronic infection protocols: pathogen-specific markers as directed by your treating physician.

Research & Citations

Biofilm disruption: Overhage J et al., “Human host defense peptide LL-37 prevents bacterial biofilm formation,” Infection and Immunity (2008). Demonstrated LL-37 prevents and disrupts P. aeruginosa biofilm formation at sub-inhibitory concentrations.

Antimicrobial spectrum: Turner J et al., “Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils,” Antimicrobial Agents and Chemotherapy (1998). Characterized LL-37’s broad-spectrum antimicrobial activity.

Immune modulation: Scott MG et al., “The human antimicrobial peptide LL-37 is a multifunctional modulator of innate immune responses,” Journal of Immunology (2002). Demonstrated LL-37’s role in immune cell recruitment and modulation beyond direct killing.

Wound healing: Heilborn JD et al., “The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds,” Journal of Investigative Dermatology (2003). Established LL-37’s wound healing properties.

Related Protocols

• Thymosin Alpha-1 Protocol — immune modulation (complementary mechanism)
• KPV Protocol — anti-inflammatory peptide (often used alongside LL-37)
• BPC-157 Protocol — tissue repair
• Peptide Safety Guide — injection technique, storage, general safety
• Reconstitution Calculator — dosing math for your vials